Effects of insulin-loaded chitosan-alginate nanoparticle on RAGE expression and oxidative stress status in the kidney tissue of rats with type 1 diabetes

Document Type : Original Article


Department of Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran


Objective(s): Chronic hyperglycemia leads to activation of the advanced glycation end products (AGE)-receptor (RAGE) for AGE axis and oxidative stress, which promote diabetic renal damage. This study examines the effect of insulin-loaded trimethyl chitosan nanoparticles on the kidney tissue of diabetic rats.
Materials and Methods: Twenty-five male Wistar rats were randomly divided into 5 groups: normal control (C), diabetic group without treatment (DM), diabetic group treated with chitosan-based nanoparticle (DM+NP, 1 ml by gavage), diabetic group treated with 8 IU/kg insulin-loaded trimethyl chitosan nanoparticles (DM+N.in, 1 ml by gavage), and diabetic group treated with 8 IU/kg trade insulin (DM+SC.in, 0.2 ml by subcutaneous injection). The animals were treated from weeks 8 to 10. At the end of the study, serum urea, creatinine, and uric acid were measured. Also, the level of AGE and RAGE mRNA expression, and oxidative stress markers were studied in the kidney tissue.
Results: Insulin-loaded nanoparticles similar to trade insulin could significantly reduce urea, creatinine, and uric acid parameters, while the elevated total antioxidant capacity (TAC), thiol groups, and catalase activity also reduced total oxidant status (TOS) and malondialdehyde (MDA) levels (P<0.05). However, the reduction in AGE and RAGE mRNA expression is not statistically significant in both treatments. Of course, the influence of insulin-loaded trimethyl chitosan nanoparticles on the amelioration of all these parameters is higher compared to that of the injected form. No markedly significant differences were observed between these two kinds of treatments.
Conclusion: This data reveals that insulin-loaded trimethyl chitosan nanoparticle is a better therapeutic approach than injected insulin.


Main Subjects

1. Kim YS, Jung DH, Sohn E, Lee YM, Kim C-S, Kim JS. Extract of Cassiae semen attenuates diabetic nephropathy via inhibition of advanced glycation end products accumulation in streptozotocin-induced diabetic rats. Phytomedicine 2014; 21:734-739.
2. Liu Y-W, Zhu X, Zhang L, Lu Q, Wang J-Y, Zhang F, et a. Up-regulation of glyoxalase 1 by mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats. Eur J Pharmacol 2013; 721:355-364.
3. Ahmed N. Advanced glycation endproducts—role in pathology of diabetic complications. Diabetes Res Clin Prac 2005; 67:3-21.
4. Liu K, Xu H, Lv G, Liu B, Lee MKK, Lu C, et al Loganin attenuates diabetic nephropathy in C57BL/6J mice with diabetes induced by streptozotocin and fed with diets containing high level of advanced glycation end products. Life Sci 2015; 123:78-85.
5. Yan SF, Barile GR, D’Agati V, Du Yan S, Ramasamy R, Schmidt AM. The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications. Curr Diab Rep 2007; 7:146-153.
6. Liu W-h, Hei Z-q, Nie H, Tang F-t, Huang H-q, Li X-j, et al Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. Chin Med J 2008; 121:706-712.
7. Guglielmotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, et al AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation. Neurobiol Aging 2012; 33:196.e113-196.e127.
8. Yamabe N, Yokozawa T, Oya T, Kim M. Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. J Pharmacol Exp Ther 2006; 319:228-236.
9. Mukhopadhyay P, Mishra R, Rana D, Kundu PP. Strategies for effective oral insulin delivery with modified chitosan nanoparticles: A review. Prog Polym Sci 2012; 37:1457-1475.
10. Gordon Still J. Development of oral insulin: Progress and current status. Diabetes Metab Res Rev 2002; 18:S29-S37.
11. Sharma G, Sharma AR, Nam J-S, Doss GPC, Lee S-S, Chakraborty C. Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes. J Nanobiotechnology 2015; 13:74.
12. Mahjub R, Radmehr M, Dorkoosh FA, Ostad SN, Rafiee-Tehrani M. Lyophilized insulin nanoparticles prepared from quaternized N-aryl derivatives of chitosan as a new strategy for oral delivery of insulin: in vitro, ex vivo and in vivo characterizations. Drug Dev Ind Pharm 2013; 40:1645-1659.
13. Stevanovic M, Uskokovic D. Poly (lactide-co-glycolide)-based micro and nanoparticles for the controlled drug delivery of vitamins. Curr Nanosci 2009; 5:1-14.
14. Gan Q, Wang T. Chitosan nanoparticle as protein delivery carrier—systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B Biointerfaces 2007; 59:24-34.
15. Fleming TH, Theilen T-M, Masania J, Wunderle M, Karimi J, Vittas S, et al Aging-dependent reduction in glyoxalase 1 delays wound healing. Gerontol 2013; 59:427-437.
16. Olson BJ, Markwell J. Assays for determination of protein concentration. Curr Protoc Protein Sci 2007:3.4. 1-3.4. 29.
17. Benzie IF, Szeto Y. Total antioxidant capacity of teas by the ferric reducing/antioxidant power assay. J Agric Food Chem 1999; 47:633-636.
18. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38:1103-1111.
19. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994; 233:380-385.
20. Hadwan MH, Abed HN. Data supporting the spectrophotometric method for the estimation of catalase activity. Data Brief 2016; 6:194-199.
21. Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002; 51:597-604.
22. Yamamoto H, Watanabe T, Yamamoto Y, Yonekura H, Munesue S, Harashima A, et al RAGE in diabetic nephropathy. Curr Mol Med 2007; 7:752-757.
23. Burns N, Gold B. The Effect of 3-Methyladenine DNA Glycosylase–Mediated DNA Repair on the Induction of Toxicity and Diabetes by the β-Cell Toxicant Streptozotocin. Toxicol Sci 2006; 95:391-400.
24. Mukhopadhyay P, Chakraborty S, Bhattacharya S, Mishra R, Kundu PP. pH-sensitive chitosan/alginate core-shell nanoparticles for efficient and safe oral insulin delivery. Int J Biol Macromol 2015; 72:640-648.
25. Kreuter J. Nanoparticles—a historical perspective. Int J Pharm 2007; 331:1-10.
26. Kowapradit J, Opanasopit P, Ngawhiranpat T, Apirakaramwong A, Rojanarata T, Ruktanonchai U, et al Methylated N-(4-N, N-dimethylaminobenzyl) chitosan, a novel chitosan derivative, enhances paracellular permeability across intestinal epithelial cells (Caco-2). AAPS PharmSciTech 2008; 9:1143-1152.
27. Mahjub R, Radmehr M, Dorkoosh FA, Ostad SN, Rafiee-Tehrani M. Lyophilized insulin nanoparticles prepared from quaternized N-aryl derivatives of chitosan as a new strategy for oral delivery of insulin: in vitro, ex vivo and in vivo characterizations. Drug Dev Ind Pharm 2014; 40:1645-1659.
28. Sahu SK. Development and evaluation of insulin incorporated nanoparticles for oral administration. ISRN Nanotechnology 2013; 2013: Article ID 591751, 6 pages.
29. Samadder A, Das J, Das S, De A, Saha SK, Bhattacharyya SS, et al Poly (lactic-co-glycolic) acid loaded Insulin-loaded trimethyl chitosan nanoparticles has greater potentials of combating arsenic induced hyperglycemia in mice: some novel findings. Toxicol Appl Pharmacol 2013; 267:57-73.
30. Green M, Miller LL. Protein catabolism and protein synthesis in perfused livers of normal and alloxan-diabetic rats. J Bioll Chem 1960; 235:3202-3208.
31. Sugimoto Ki, Tsuruoka S, Fujimura A. Effect of enalapril on diabetic nephropathy in oletf rats: the role of an anti‚Äźoxidative action in its protective properties. Clin Exp Pharmacol Physiol 2001; 28:826-830.
32. Kuhad A, Chopra K. Attenuation of diabetic nephropathy by tocotrienol: involvement of NFkB signaling pathway. Life Sci 2009; 84:296-301.
33. Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid—a facet of hyperinsulinaemia. Diabetologia 1987; 30:713-718.
34. Palsamy P, Subramanian S. Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed Pharmacother 2008; 62:598-605.
35. Haidara MA, Mikhailidis DP, Rateb MA, Ahmed ZA, Yassin HZ, Ibrahim IM, et al Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced type 1 diabetes. J Diabetes Complications 2009; 23:130-136.
36. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107:1058-1070.
37. West IC. Radicals and oxidative stress in diabetes. Diabetic Medicine 2000; 17:171-180.
38. Manigrasso MB, Juranek J, Ramasamy R, Schmidt AM. Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab 2014; 25:15-22.
39. Monnier VM, Sell DR, Nagaraj RH, Miyata S, Grandhee S, Odetti P, et al Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 1992; 41:36-41.
40. Ng AXH, Ton SH. Low-dose Insulin treatment ameliorate glucose metabolism in tpe 1 diabetic rats. J Diabetes Metab 2015; 07.
41. Yamagishi S-i, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 2010; 3:101-108.
42. Sano H, Higashi T, Matsumoto K, Melkko J, Jinnouchi Y, Ikeda K, et al Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products. J Biol Chem1998; 273:8630-8637.